M&A / Deals Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal BioPharma DiveThe purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.Rare DiseaseRead full story pharminent July 1, 2026 (Last updated: July 1, 2026) BioPharma Dive The purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AlzeCure enters collaboration agreement with QuantumCell ApS for NeuroRestore projectNext: Decoding Medicare Advantage Coding Intensity Related Stories M&A / Deals Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront pharminent August 11, 2026 M&A / Deals Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments pharminent August 7, 2026 M&A / Deals Supernus and Indivior merge to create scaled, CNS-focused entity pharminent August 4, 2026
